Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04QZD
|
|||
| Former ID |
DNC000619
|
|||
| Drug Name |
Eslicarbazepine
|
|||
| Synonyms |
Aptiom; BIA 2-093; Exalief; SEP-0002093; Sep-93; Stedesa; Zebinix
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Seizure disorder [ICD-11: 8A6Z; ICD-9: 345.9, 780.3] | Approved | [1], [2] | |
| Therapeutic Class |
Neurology Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H14N2O2
|
|||
| Canonical SMILES |
C1C(C2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N)O
|
|||
| InChI |
1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)/t14-/m0/s1
|
|||
| InChIKey |
BMPDWHIDQYTSHX-AWEZNQCLSA-N
|
|||
| CAS Number |
CAS 104746-04-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14847818, 24169052, 45628457, 61013447, 74832373, 96025895, 103293530, 118310966, 126665681, 127537462, 135253067, 143479487, 162188093, 163124654, 163696949, 164230651, 164763126, 172860101, 175266523, 178103922, 198977350, 204360581, 219401211, 223533430, 223653619, 224675811, 226744763, 249855365, 250218635, 252077440, 252429028
|
|||
| ADReCS Drug ID | BADD_D00811 | |||
| SuperDrug ATC ID |
N03AF04
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Blocker | [3] |
| Voltage-gated sodium channel (Nav) | Target Info | Inhibitor | [4] | |
| Voltage-gated sodium channel alpha Nav1.9 (SCN11A) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7350). | |||
| REF 2 | Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. | |||
| REF 3 | Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. | |||
| REF 4 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.